Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
NCT05552755 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 67
Last updated 2026-04-16
Summary
This is a multicenter, two-part trial in participants with FAP.
Conditions
Interventions
Sponsors & Collaborators
-
Recursion Pharmaceuticals Inc.
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-07-10
- Primary Completion
- 2027-06-30
- Completion
- 2027-09-30
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis
NCT02718495 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis
NCT03140527 ·Status: COMPLETED ·Phase: PHASE1
-
PK Study of N91115 in Cystic Fibrosis Patients
NCT02227888 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis
NCT04853368 ·Status: TERMINATED ·Phase: PHASE2
-
Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis
NCT03591094 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation
NCT03068312 ·Status: COMPLETED ·Phase: PHASE3
-
Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic Fibrosis
NCT00004806 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Determine the Efficacy&Safety of ARV-1801(ACG-701) for the Treatment of Cystic Fibrosis Pulmonary Exacerbations
NCT05641298 ·Status: WITHDRAWN ·Phase: PHASE2
-
Analysis of Specimens From Individuals With Pulmonary Fibrosis
NCT00084305 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis
NCT03119649 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.
NCT03540524 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor
NCT02724527 ·Status: UNKNOWN ·Phase: PHASE2
-
Action of Epigenetic Modifiers in Cystic Fibrosis Treatment
NCT01883284 ·Status: COMPLETED ·Phase: NA
-
Miglustat in Cystic Fibrosis
NCT00742092 ·Status: COMPLETED ·Phase: PHASE2
-
Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials
NCT03531814 ·Status: COMPLETED ·Phase: NA
-
Diagnosis and Treatment of Patients With Cystic Fibrosis
NCT00001223 ·Status: TERMINATED
-
A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis
NCT03045523 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II , Placebo-controlled Study to Assess Efficacy of 28 Day Oral AZD9668 in Patients With Cystic Fibrosis
NCT00757848 ·Status: COMPLETED ·Phase: PHASE2
-
Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation
NCT02275936 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis
NCT03375047 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
NCT06237335 ·Status: RECRUITING ·Phase: PHASE2
-
Miglustat / OGT 918 in the Treatment of Cystic Fibrosis
NCT00537602 ·Status: TERMINATED ·Phase: PHASE2
-
Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF
NCT06468527 ·Status: COMPLETED ·Phase: PHASE2
-
Description of the Short-term Effects of KAFTRIO® by Continuous Monitoring With the PHEAL-CR-K Application in Real Life in Patients With Cystic Fibrosis Eligible for KAFTRIO® Treatment
NCT05295524 ·Status: UNKNOWN ·Phase: NA
-
Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation
NCT02325362 ·Status: COMPLETED ·Phase: PHASE2/PHASE3